Literature DB >> 14588099

Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy.

Michele Marinò1, Simonetta Lisi, Aldo Pinchera, Claudio Marcocci, Francesca Menconi, Eugenia Morabito, Marco Macchia, Stefano Sellari-Franceschini, Robert T McCluskey, Luca Chiovato.   

Abstract

The presence of thyroglobulin (Tg) in orbital tissues of patients with thyroid-associated ophthalmopathy (TAO) supports a role of Tg in TAO pathogenesis. To search for Tg-binding sites in orbital tissues, because Tg is a heparin-binding protein, we investigated its binding to glycosaminoglycans (GAGs) that are abundant in orbital tissues: chondroitin sulfate B (CSB) and C (CSC) and hyaluronic acid (HA). Both in solid phase and solution phase assays purified human Tg bound to GAGs. In solid-phase assays, binding was increased by coincubation with heparin or GAGs in solution, or with an antibody against a Tg heparin-binding sequence (Arg2489-Glu2503), possibly suggesting crosslinking of Tg molecules induced by GAGs or by the presumably bivalent antibody. Orbital tissue extracts from TAO patients that contained Tg were subjected to high-salt treatment, which resulted in separation of Tg from GAGs, as observed by column chromatography. After separation from GAGs, the Tg in orbital tissue extracts acquired the ability to bind to immobilized CSB, and heparin enhanced binding, resembling the findings with purified human Tg. Therefore, we conclude that GAGs provide binding sites for Tg in orbital tissues, which may explain the presence of Tg in orbital tissues of patients with TAO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14588099     DOI: 10.1089/105072503322401041

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

Review 1.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

Review 2.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

3.  Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves' ophthalmopathy.

Authors:  S Lisi; R Botta; P Agretti; S Sellari-Franceschini; C Marcocci; A Pinchera; M Marinò
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

4.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29

Review 5.  Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.

Authors:  Terry J Smith
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-01-31       Impact factor: 4.690

Review 6.  Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited.

Authors:  M Marinò; L Chiovato; S Lisi; M A Altea; C Marcocci; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 7.  New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor.

Authors:  Terry J Smith
Journal:  F1000Res       Date:  2018-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.